Testing tirabrutinib against a two-drug combination for primary CNS lymphoma that came back
Official title: IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This trial compares one drug, tirabrutinib, with a two-drug treatment in people whose primary central nervous system lymphoma has come back or did not respond.
Read our full plain-language summary
What the trial team says
The purpose of this clinical trial is to evaluate efficacy and safety of tirabrutinib alone compared with rituximab and temozolomide (R-TMZ) combination therapy in participants with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL).
Key facts
- Registry number
- NCT07104032
- Stage of testing
- Phase 3
- Conditions studied
- Relapsed/Refractory Primary Central Nervous System Lymphoma
Where it is running
This trial lists 32 sites.
-
Arizona
- Mayo Clinic Cancer Center (Phoenix)
- HonorHealth Cancer Center (Scottsdale)
-
California
- Providence Medical Foundation (Fullerton)
- UC Irvine Health (Orange)
-
Connecticut
- Yale Cancer Center (New Haven)
-
Czechia
- University Hospital Ostrava (Ostrava)
- University Hospital Královské Vinohrady (Prague)
-
District of Columbia
- John Hopkins University (Washington D.C.)
-
Florida
- University of Florida Gainesville (Gainesville)
- Mayo Clinic Cancer Center (Jacksonville)
-
France
- Hôpitaux de Marseille (Marseille)
- Hospital Center University De Montpellier (Montpellier)
-
Italy
- ASST Spedali Civili di Brescia (Brescia)
- IRCCS Istituto Romagnolo per lo studio dei Tumori "Dino Amadori" - IRST (Meldola)
-
Maryland
- University of Maryland (Baltimore)
-
Massachusetts
- Massachusetts General Hospital (Boston)
- Beth Israel Deaconess Medical Center (Boston)
- Dana-Farber Cancer Institute (Boston)
-
Minnesota
- Mayo Clinic Cancer Center (Rochester)
-
New Jersey
- Hackensack University Medical Center (Hackensack)
- Atlantic Health Overlook Medical Center (Summit)
-
New York
- NYU Langone Health (New York)
- Columbia University Irving Medical Center (New York)
- Memorial Sloan Kettering Cancer Center (New York)
-
North Carolina
- Duke University Medical Center (Durham)
-
Oregon
- Providence Neurological Specialties West (Portland)
-
Pennsylvania
- Penn State Health Milton S Hershey Medical Center (Hershey)
- UPMC Hillman Cancer Center (Pittsburgh)
-
Rhode Island
- Rhode Island Hospital (Providence)
-
Spain
- Hospital Clínic de Barcelona (Barcelona)
- Hospital Universitario 12 De Octubre (Madrid)
-
Victoria
- Epworth Healthcare (Melbourne)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.